Epilepsy is one of the most common chronic neurological conditions in dogs, affecting approximately 0.75% of the pet dog population. With appropriate management, many epileptic dogs can achieve good quality of life, but untreated or poorly managed epilepsy causes significant welfare harm.
Canine epilepsy welfare spans the seizure event itself, the post-ictal period, and the long-term impact of chronic disease management. Generalised seizures involve loss of consciousness, motor convulsions, and physiological events (hyperthermia, oxygen desaturation, potential physical injury from falls or impact) that may or may not involve conscious suffering depending on seizure type. The post-ictal period — often more distressing for owners to observe than the seizure — causes temporary neurological impairment that is likely confusing and frightening for dogs who cannot understand what has happened to them. Chronic antiepileptic medication carries side effects including sedation, ataxia, polyphagia, and in the case of phenobarbitone, long-term hepatotoxicity that requires monitoring. For drug-resistant epileptic dogs, the welfare challenge is balancing seizure frequency against medication side-effect burden. Quality of life assessment tools specifically developed for epileptic dogs help owners and veterinarians make informed decisions about when escalating treatment, palliative management, or euthanasia best serves the animal's welfare.